Voyager Therapeutics' (VYGR) shares dropped nearly 13% in recent Tuesday trading after the company said it no longer expects to file an investigational new drug application for VY9323 in mid-2025.
The biotechnology company reported an obstacle in its superoxide dismutase 1 amyotrophic lateral sclerosism, or SOD1 ALS, gene therapy program, as three-month non-human primate data revealed the need to assess alternate payloads for VY9323, while maintaining the use of the novel capsid component.
This change extends the company's cash runway until mid-2027, not accounting for possible milestone payments from partnerships, the company said, adding that it will provide an update on the SOD1 ALS program timeline as it continues evaluating alternative payloads.
This decision does not impact the company's other gene therapy programs, with IND filings still expected in 2025 from Neurocrine Biosciences (NBIX) for the GBA1 Parkinson's and GBA1-mediated disease program, as well as the Friedreich's ataxia program, while Voyager also anticipates filing an IND for VY1706 (tau silencing) gene therapy program in 2026, the company said.
Price: 4.64, Change: -0.69, Percent Change: -12.88
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。